trending Market Intelligence /marketintelligence/en/news-insights/trending/kHjGXtSyu68gcoalp_j4gg2 content esgSubNav
In This List

Ascendis Pharma closes ADS offering

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Ascendis Pharma closes ADS offering

Ascendis Pharma A/S closed an underwritten public offering of 3.8 million American depositary shares for net proceeds of about $126.1 million.

The company priced the ADSs, each of which represents 1 ordinary share, at $35.50 apiece.

Underwriters also received a 30-day option to buy up to an additional 570,000 ADSs.

Underwriters were J.P. Morgan Securities LLC, Merrill Lynch, Pierce Fenner & Smith Inc., Credit Suisse Securities (USA) LLC, Wells Fargo Securities LLC and Wedbush Securities Inc.